acute coronary syndrome. Other acute ischemic heart diseases
Conditions
Interventions
Intervention 1: Control group: Receiving the standard dose of eptifibatide (bolus with infusion), that is, in addition to the bolus dose, a 12-18-hour infusion will be administered. Two separate doses
Sponsors
Rasht University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: All patients over 18 years old that have below characteristics patient with acute coronary syndrome patient treated with eptifibatide during angioplasty based on the diagnosis of the attending physician
Exclusion criteria
Exclusion criteria: If a patient with thrombocytopenia (platelets below 100,000) bleeding (gastrointestinal, cerebral, pulmonary) a history of intracranial events (neoplasm, arteriovenous malformation, cerebral aneurysm) severe renal dysfunction (creatinine clearance below 50) patients for whom Fibrinolytics have been prescribed in the last 24 hours
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy and safety of reduced dose compared to standard eptifibatide in patients with acute coronary syndrome. Timepoint: Check the results after 90 days. Method of measurement: Efficacy and safety of the reduced dose compared to the standard eptifibatide in patients with acute coronary syndrome is how to check the mechanical outcomes after 90 days through echocardiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaede Dadras
Rasht University of Medical Sciences
Outcome results
None listed